- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Vertex Pharmaceuticals Inc. (VRTX)
by latest | most commented
-
Is IBB the Best Biotech ETF?
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Thursday Options Update: FXI, IYR, YGE, VRTX & XLF
-
Vertex: Long Term Buy Opportunity
-
Where the Big Money Is Betting Big
-
Thursday Options Update: XRT, CLF, WFMI & VRTX
-
Sequenom's Bombshell
-
A Look at D.E. Shaw's Q408 Holdings: Just for Fun
-
Tudor Investment Takes New Positions in Financials, Among Others
-
Biotech Is Now the Place to Be for Big Pharma
-
Biopharma: Instead of M&A, Think P&A
-
Vertex to Buy Hepatitis C Drug Developer ViroChem for $375 Million
-
80 Winning Stocks That Have Nothing to Do with Gold
-
IBB: Newfound Stability Lures Biotech Investors
-
Biotechnology: The New Defensive Sector That's Set to Rise?
-
Hedge Fund Portfolio Tracking: D.E. Shaw & Co (David E. Shaw), Q3 2008
-
How Is the Biotech Industry Holding Up?
-
9 Possible Pharma Deals for 2009
-
2009: Positive Outlook for Biotech
-
2008 Stock Market: 51 Rays of Light
-
Fast Money Recap - Bullish on Biotech (1/5/09)
-
Hedge Fund Tracking: Farallon Capital Management (Thomas Steyer), Q3 2008
-
Pharma Stocks Buck the Market Trend
-
Vertex's $75K Question
-
Nasdaq 100 Struggles
-
5 Potential Buyout Targets in Biotech - Barron's
-
Earnings Preview: Vertex Pharmaceuticals
-
Big Biotech Booms But IBB Falls Flat
-
Biotech Fundamentals Still Look Strong
-
Russell 1,000 Stocks Up and Down the Most Since the 3/10 Bottom
-
FDA's "Risky Business" for Pharma & Biotech
-
Schering Beat the Street and Plows Through Vytorin Firestorm
-
Stocks with Biggest Gains Last Week; Furthest Above 50-DMAs
-
Best and Worst Performers Since the 3/10 Bottom
-
Vertex's Telaprevir May Become a Multi-Billion Dollar Drug
-
Vytorin Battle Pits Merck and SGP against Pfizer
-
Insider Buying in Biotech Land
-
Healthcare Stocks Have Been Anything but Defensive
-
Earnings Preview: Vertex Pharmaceuticals
-
Hepatitis C Developments Drag Biotechs Down
-
2007 Biotech Performance Review